Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

Slides:

Advertisements

Similar presentations

Clinical Impression: BRONCHOGENIC CARCINOMA. Small cell lung carcinoma 20 % of lung cancer Anaplastic and highly malignant Displays neuroendocrine properties.

Advertisements

TCGA(The cancer genome atlas) catalogue genetic mutations responsible for cancer, using genome sequencing and bioinformatics The TCGA is sequencing the.

KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.

EGFR gene mutation testing in NSCLC

Jennie Bell CMGS/ACC Spring meeting 14 th April 2010.

Supplementary Figure 1. Somatic mutation spectrum # Substitutions # Substitutions per Mb b c a Repeats Pseudogenes Whole genome Splice sites Non-coding.

2015/ NON-SMALL CELL LUNG CANCER (NSCLC) 1.1 Adenocarcinomas are often found in an outer area of the lung. 1.2 Squamous cell carcinomas are usually.

ICNCT-16, June 2014, Helsinki Glioma heterogeneity and the L-Amino acid transporter-1 (LAT1): A first step to stratified BPA-based BNCT? D. Ngoga 1 ; C.

Cell lineStatus FGFR1 DMS-114Gene amplification NCI-H520Gene amplification NCI-H1581Gene amplification FGFR2 NCI-H716Gene amplification KATO-IIIGene amplification.

Main Figures and Tables. Figure 1 Strategy (shall we make a strategy figure here?? ）

YEATS4 Is a Novel Oncogene Amplified in Non– Small Cell Lung Cancer That Regulates the p53 Pathway Speaker:Dai-Wei Hsuan Adviser:Dr. Guor-Mour, Her Data:2015/04/22.

MOLECULAR DIAGNOSTICS IN ONCOLOGY Dr. Sergey Kovalenko.

Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;

Marker SFRP1 SFRP2 SFRP5 DKK3 WIF1 APC CDH1 Unmethylated Methylated A

Main Figures and Tables

Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Hallett, et al., - Supplementary Figure 1

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

Lu Chen, PhD, Brienne E. Engel, PhD, Eric A. Welsh, PhD, Sean J

ERBB2-Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies Jody C. Chuang, MD, PhD, Henning Stehr, PhD, Ying.

Red: stable co-clustering Blue: no co-clustering

Volume 9, Issue 6, Pages (June 2006)

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma Nicolas Guibert,

Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma

Revealing the genomic heterogeneity of melanoma

Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

Volume 9, Issue 6, Pages (June 2006)

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

Volume 140, Issue 3, Pages e8 (March 2011)

Volume 3, Issue 4, Pages (April 2003)

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers Carla Verri, MSc, Cristina Borzi, MSc, Todd Holscher,

Tumor Cell Content for Selection of Molecular Techniques for T790M EGFR Mutation Detection in Non-small Cell Lung Cancer Nathalie Prim, Elisabeth Quoix,

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Anya M. Litvak, MD, Paul K. Paik, MD, Kaitlin M. Woo, MS, Camelia S

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas Bin Gao, BS, Yihua Sun, MD, Junhua Zhang, MD, Yan Ren, PhD, Rong Fang, BS,

Ernest Nadal, MD, Guoan Chen, MD, PhD, John R

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Lung Adenocarcinoma Harboring Mutations in the ERBB2 Kinase Domain

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Reduced BAI1 expression is associated with breast cancer patient survival. Reduced BAI1 expression is associated with breast cancer patient survival. A,

Methylation-specific PCR of APC, RASSF1A, and p14ARF genes in bladder tumor and urine DNAs. In the APC gel panel viewed from left to right, the first (TCC34)

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Molecular definitions of lung adenocarcinoma subtypes.

EZH2-driven lung cancer as a molecularly distinct entity.

Volume 3, Issue 4, Pages (April 2003)

Presentation transcript:

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer patients. P values were calculated using logrank test. A. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value of 3 or more per cell (all samples). B. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value of 2.5 or more per cell (all samples). C. RASSF1A methylated (M) versus unmethylated (U) (all samples). D. EGFR mutated (M) versus wild type (WT) [all samples]. E. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (all samples). F. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (adenocarcinoma). G. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (squamous cell carcinoma). H. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; and p53 mutated, at least one altered, COMBO (+P53)) versus no alteration (squamous cell carcinoma).

A. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value of 3 or more per cell (all samples). Months P=0.64

Months P=0.38 B. EGFR amplified (amp) versus normal (no amp), considering as amplified patients with a value of 2.5 or more per cell (all samples).

Months P=0.99 C. RASSF1A methylated (M) versus unmethylated (U) (all samples).

D. EGFR mutated (M) versus wild type (WT) [all samples]. Months P=0.64

Months P=0.63 E. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (all samples).

Months P=0.74 F. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (adenocarcinoma)

Months P=0.93 G. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; at least one altered, COMBO) versus no alteration (squamous cell carcinoma).

Months P=0.09 H. erbB signaling pathway genes (EGFR mutated or amplified, Braf mutated, Kras mutated, RASSF1A methylated; and p53 mutated, at least one altered, COMBO (+P53)) versus no alteration (squamous cell carcinoma).